Transmembrane mucins as novel therapeutic targets

References

• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer9(12), 874–885 (2009).
   PubMed Web of Science ®Google Scholar
• Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer4(1), 45–60 (2004).
   PubMed Web of Science ®Google Scholar
• Choudhury A, Moniaux N, Ringel J et al. Alternate splicing at the 3’-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog. Carcinog. Mutagen.21(1), 83–96 (2001).
   PubMedGoogle Scholar
• Wreschner DH, Hareuveni M, Tsarfaty I et al. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur. J. Biochem.189(3), 463–473 (1990).
   PubMedGoogle Scholar
• Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem.267(9), 6171–6177 (1992).
   PubMed Web of Science ®Google Scholar
• Julian J, Carson DD. Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. Biochem. Biophys. Res. Commun.293(4), 1183–1190 (2002).
   PubMed Web of Science ®Google Scholar
• Sheng Z, Wu K, Carraway KL, Fregien N. Molecular cloning of the transmembrane component of the 13762 mammary adenocarcinoma sialomucin complex. A new member of the epidermal growth factor superfamily. J. Biol. Chem.267(23), 16341–16346 (1992).
   PubMed Web of Science ®Google Scholar
• Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J. Biol. Chem.278(5), 3386–3394 (2003).
   PubMed Web of Science ®Google Scholar
• Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem. J.382(Pt 1), 363–373 (2004).
   PubMed Web of Science ®Google Scholar
• Tian E, Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj. J.26(3), 325–334 (2009).
   PubMed Web of Science ®Google Scholar
• Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology13(1), R1–R16 (2003).
   PubMedGoogle Scholar
• Varki A. Selectins and other mammalian sialic acid-binding lectins. Curr. Opin. Cell. Biol.4(2), 257–266 (1992).
   PubMedGoogle Scholar
• Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol. Rev.230(1), 97–113 (2009).
   PubMed Web of Science ®Google Scholar
• Ramphal R, Arora SK. Recognition of mucin components by Pseudomonas aeruginosa. Glycoconj. J.18(9), 709–713 (2001).
   PubMedGoogle Scholar
• Evans DJ Jr, Evans DG. Helicobacter pylori adhesins: review and perspectives. Helicobacter5(4), 183–195 (2000).
   PubMed Web of Science ®Google Scholar
• Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol.70, 431–457 (2008).
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem.265(25), 15286–15293 (1990).
   PubMed Web of Science ®Google Scholar
• Hanisch FG, Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology10(5), 439–449 (2000).
   PubMed Web of Science ®Google Scholar
• Kui Wong N, Easton RL, Panico M et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem.278(31), 28619–28634 (2003).
   PubMed Web of Science ®Google Scholar
• Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell7(4), 565–577 (1996).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Carraway CA, Fregien NL, Carraway KL. Reversible disruption of cell–matrix and cell–cell interactions by overexpression of sialomucin complex. J. Biol. Chem.272(52), 33245–33254 (1997).
   PubMed Web of Science ®Google Scholar
• Carson DD, Julian J, Lessey BA, Prakobphol A, Fisher SJ. MUC1 is a scaffold for selectin ligands in the human uterus. Front. Biosci.11, 2903–2908 (2006).
   PubMed Web of Science ®Google Scholar
• Gubbels JA, Felder M, Horibata S et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer9, 11 (2010).
   PubMed Web of Science ®Google Scholar
• Belisle JA, Horibata S, Jennifer GA et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer9, 118 (2010).
   PubMed Web of Science ®Google Scholar
• Rump A, Morikawa Y, Tanaka M et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem.279(10), 9190–9198 (2004).
   PubMed Web of Science ®Google Scholar
• Carraway CA, Carraway KL. Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis. Sci. STKE2007(381), re3 (2007).
   PubMedGoogle Scholar
• Carson DD. The cytoplasmic tail of MUC1: a very busy place. Sci. Signal.1(27), pe35 (2008).
   PubMedGoogle Scholar
• Vasir B, Avigan, D, Wu et al. Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. J. Immunol.174, 2376–2386 (2005).
   PubMed Web of Science ®Google Scholar
• Vandewielvankemenade E, Ligtenberg MJL, Deboer AJ et al. Episialin (Muc1) inhibits cytotoxic lymphocyte-target cell-interaction. J. Immunol.151(2), 767–776 (1993).
   PubMedGoogle Scholar
• Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res.59(9), 2229–2236 (1999).
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med.4(1), 43–49 (1998).
   PubMed Web of Science ®Google Scholar
• Patankar MS, Jing Y, Morrison JC et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol.99(3), 704–713 (2005).
   PubMed Web of Science ®Google Scholar
• Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem.270(50), 30093–30101 (1995).
   PubMed Web of Science ®Google Scholar
• Kardon R, Price RE, Julian J et al. Bacterial conjunctivitis in Muc1 null mice. Invest. Ophthalmol. Vis. Sci.40(7), 1328–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Danjo Y, Hazlett LD, Gipson IK. C57BL/6 mice lacking Muc1 show no ocular surface phenotype. Invest. Ophthalmol. Vis. Sci.41(13), 4080–4084 (2000).
   PubMed Web of Science ®Google Scholar
• Cheon DJ, Wang Y, Deng JM et al. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One4(3), e4675 (2009).
   Google Scholar
• Jonckheere N, Van Seuningen I. The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie92(1), 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Gendler SJ. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia6(3), 339–353 (2001).
   PubMed Web of Science ®Google Scholar
• Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod. Biol. Endocrinol.2, 4 (2004).
   PubMedGoogle Scholar
• Dent GA, Civalier CJ, Brecher ME, Bentley SA. MUC1 expression in hematopoietic tissues. Am. J. Clin. Pathol.111(6), 741–747 (1999).
   PubMed Web of Science ®Google Scholar
• Chang JF, Zhao HL, Phillips J, Greenburg G. The epithelial mucin, MUC1, is expressed on resting T lymphocytes and can function as a negative regulator of T cell activation. Cell. Immunol.201(2), 83–88 (2000).
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Parker J, Longenecker BM. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res.58(18), 4079–4081 (1998).
   PubMed Web of Science ®Google Scholar
• Franke FE, Kraus S, Eiermann C, Pauls K, Lalani EN, Bergmann M. MUC1 in normal and impaired spermatogenesis. Mol. Hum. Reprod.7(6), 505–512 (2001).
   PubMedGoogle Scholar
• Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J.22(4), 966–981 (2008).
   PubMed Web of Science ®Google Scholar
• Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthalmol. Vis. Sci.44(6), 2487–2495 (2003).
   PubMed Web of Science ®Google Scholar
• Davies JR, Kirkham S, Svitacheva N, Thornton DJ, Carlstedt I. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int. J. Biochem. Cell. Biol.39(10), 1943–1954 (2007).
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Offner FA, Muller-Holzner E et al. Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumour Biol.19(4), 275–282 (1998).
   PubMedGoogle Scholar
• Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil. Steril.59(5), 1028–1035 (1993).
   PubMed Web of Science ®Google Scholar
• Nustad K, Lebedin Y, Lloyd KO et al. Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop. Tumour Biol.23(5), 303–314 (2002).
   PubMedGoogle Scholar
• O’Connor JC, Julian J, Lim SD, Carson DD. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis.8(1), 36–44 (2005).
   PubMedGoogle Scholar
• Singh AP, Chauhan SC, Bafna S et al. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate66(4), 421–429 (2006).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med.309(15), 883–887 (1983).
   PubMed Web of Science ®Google Scholar
• Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer12(4), 372–375 (2002).
   PubMed Web of Science ®Google Scholar
• Carson DD, Dharmaraj N, Wang P. Transcriptional control of the expression of MUC1. Expert Rev. Endocrinol. Metab.3(4), 463–471 (2008).
   PubMedGoogle Scholar
• McNeer RR, Carraway CA, Fregien NL, Carraway KL. Characterization of the expression and steroid hormone control of sialomucin complex in the rat uterus: implications for uterine receptivity. J. Cell. Physiol.176(1), 110–119 (1998).
   PubMed Web of Science ®Google Scholar
• Idris N, Carraway KL. Sialomucin complex (Muc4) expression in the rat female reproductive tract. Biol. Reprod.61(6), 1431–1438 (1999).
   PubMed Web of Science ®Google Scholar
• Lange C, Fernandez J, Shim D, Spurr-Michaud S, Tisdale A, Gipson IK. Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of mice. Exp. Eye Res.77(1), 59–68 (2003).
   PubMed Web of Science ®Google Scholar
• Idris N, Carraway KL. Regulation of sialomucin complex/Muc4 expression in rat uterine luminal epithelial cells by transforming growth factor-β: implications for blastocyst implantation. J. Cell. Physiol.185(2), 310–316 (2000).
   PubMedGoogle Scholar
• Gipson IK, Ho SB, Spurr-Michaud SJ et al. Mucin genes expressed by human female reproductive tract epithelia. Biol. Reprod.56(4), 999–1011 (1997).
   PubMed Web of Science ®Google Scholar
• Gipson IK, Blalock T, Tisdale A et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol. Reprod.78(1), 134–142 (2008).
   PubMed Web of Science ®Google Scholar
• Brayman MJ, Julian J, Mulac-Jericevic B, Conneely OM, Edwards DP, Carson DD. Progesterone receptor isoforms A and B differentially regulate MUC1 expression in uterine epithelial cells. Mol. Endocrinol.20(10), 2278–2291 (2006).
   PubMedGoogle Scholar
• Wang P, Dharmaraj N, Brayman MJ, Carson DD. Peroxisome proliferator-activated receptor γ activation inhibits progesterone-stimulated human MUC1 expression. Mol. Endocrinol.24(7), 1368–1379 (2010).
   PubMedGoogle Scholar
• Dharmaraj N, Wang P, Carson DD. Cytokine and progesterone receptor interplay in the regulation of MUC1 gene expression. Mol. Endocrinol.24(12), 2253–2266 (2010).
   PubMedGoogle Scholar
• Perrais M, Pigny P, Ducourouble MP et al. Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J. Biol. Chem.276(33), 30923–30933 (2001).
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Singh AP, Nemos C et al. IFN-γ-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-γ response. Oncogene26(51), 7251–7261 (2007).
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Perrais M, Mariette C et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-β in pancreatic carcinogenesis. Oncogene23(34), 5729–5738 (2004).
   PubMed Web of Science ®Google Scholar
• Choudhury A, Singh RK, Moniaux N, El-Metwally TH, Aubert JP, Batra SK. Retinoic acid-dependent transforming growth factor-β 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-α signaling pathway. J. Biol. Chem.275(43), 33929–33936 (2000).
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Agrawal A, Singh AP et al. Synergistic induction of the MUC4 mucin gene by interferon-γ and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene24(40), 6143–6154 (2005).
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Vincent A, Perrais M et al. The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. J. Biol. Chem.282(31), 22638–22650 (2007).
   PubMedGoogle Scholar
• Piessen G, Jonckheere N, Vincent A et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1α. Biochem. J.402(1), 81–91 (2007).
   PubMedGoogle Scholar
• Albertsmeyer AC, Kakkassery V, Spurr-Michaud S, Beeks O, Gipson IK. Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells. Exp. Eye Res.90(3), 444–451 (2010).
   PubMed Web of Science ®Google Scholar
• Thapi A, Binder D, Roseales N, Yan XJ, Lash AE, Spriggs DR. Transcription factors that regulate MUC16 expression in ovarian cancer. Presented at: AACR 102nd Annual Meeting. Orlando, FL, USA, 2–6 April 2011.
   Google Scholar
• Van Seuningen I, Vincent A. Mucins: a new family of epigenetic biomarkers in epithelial cancers. Expert Opin. Med. Diagnostics3(4), 411–442 (2009).
   PubMedGoogle Scholar
• Smorodinsky N, Weiss M, Hartmann ML et al. Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. Biochem. Biophys. Res. Commun.228(1), 115–121 (1996).
   PubMedGoogle Scholar
• Zrihan-Licht S, Vos HL, Baruch A et al. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur. J. Biochem.224(2), 787–795 (1994).
   PubMedGoogle Scholar
• Baruch A, Hartmann M, Zrihan-Licht S et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int. J. Cancer71(5), 741–749 (1997).
   PubMed Web of Science ®Google Scholar
• Oosterkamp HM, Scheiner L, Stefanova MC, Lloyd KO, Finstad CL. Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int. J. Cancer72(1), 87–94 (1997).
   PubMedGoogle Scholar
• Levitin F, Baruch A, Weiss M et al. A novel protein derived from the MUC1 gene by alternative splicing and frameshifting. J. Biol. Chem.280(11), 10655–10663 (2005).
   PubMed Web of Science ®Google Scholar
• Choudhury A, Moniaux N, Winpenny JP, Hollingsworth MA, Aubert JP, Batra SK. Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J. Biochem.128(2), 233–243 (2000).
   PubMed Web of Science ®Google Scholar
• Moniaux N, Escande F, Batra SK, Porchet N, Laine A, Aubert JP. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur. J. Biochem.267(14), 4536–4544 (2000).
   PubMedGoogle Scholar
• Briggs S, Price MR, Tendler SJ. Immune recognition of linear epitopes in peptide fragments of epithelial mucins. Immunology73(4), 505–507 (1991).
   PubMedGoogle Scholar
• Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J. Clin. Invest.75(5), 1671–1678 (1985).
   PubMed Web of Science ®Google Scholar
• Kufe DW. Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol. Ther.7(1), 81–84 (2008).
   PubMed Web of Science ®Google Scholar
• Nacht M, Ferguson AT, Zhang W et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Research59(21), 5464–5470 (1999).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Boyce RWG, Abd El-Rehim D et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod. Pathol.18(10), 1295–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Chauhan SC, Singh AP, Ruiz F et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol.19(10), 1386–1394 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology106(2), 353–361 (1994).
   PubMed Web of Science ®Google Scholar
• Hiraga Y, Tanaka S, Haruma K et al. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology55(4), 307–319 (1998).
   PubMed Web of Science ®Google Scholar
• Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am. J. Surg. Pathol.26(4), 466–471 (2002).
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Kijima H, Dowaki S et al. DF3 expression in human gallbladder carcinoma: significance for lymphatic invasion. Int. J. Oncol.16(3), 455–459 (2000).
   PubMed Web of Science ®Google Scholar
• Nitta T, Sugihara K, Tsuyama S, Murata F. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: association with disease progression, mode of invasion, and lymph node metastasis. Cancer88(2), 245–254 (2000).
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Kurishima K, Kagohashi K et al. Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J. Clin. Lab. Anal.24(5), 295–299 (2010).
   PubMed Web of Science ®Google Scholar
• Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J. Thorac. Oncol.1(1), 46–51 (2006).
   PubMed Web of Science ®Google Scholar
• Tsutsumida H, Goto M, Kitajima S et al. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer55(2), 195–203 (2007).
   PubMed Web of Science ®Google Scholar
• Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer88(4), 507–518 (2000).
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Kumar S et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J.25(16), 3774–3783 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang K, Baeckstrom D, Brevinge H, Hansson GC. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell. Biochem.60(4), 538–549 (1996).
   PubMed Web of Science ®Google Scholar
• Nath D, Hartnell A, Happerfield L et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology98(2), 213–219 (1999).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Tatum L, Altman NH, Carraway CAC, Carraway KL. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int. J. Cancer87(4), 480–486 (2000).
   PubMedGoogle Scholar
• Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res.58(9), 2014–2019 (1998).
   PubMed Web of Science ®Google Scholar
• Wesseling J, Vandervalk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell-adhesion to extracellular-matrix components. J. Cell. Biol.129(1), 255–265 (1995).
   PubMed Web of Science ®Google Scholar
• Carraway KL, Theodoropoulos G, Kozloski GA, Carraway CAC. Muc4/MUC4 functions and regulation in cancer. Future Oncol.5(10), 1631–1640 (2009).
   PubMed Web of Science ®Google Scholar
• Workman HC, Sweeney C, Carraway KL. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res.69(7), 2845–2852 (2009).
   PubMed Web of Science ®Google Scholar
• Comamala M, Pinard M, Theriault C et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br. J. Cancer104(6), 989–999 (2011).
   PubMed Web of Science ®Google Scholar
• Gubbels JAA, Belisle J, Onda M et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer5(1), 50 (2006).
   PubMed Web of Science ®Google Scholar
• Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell. Sci.116(7), 1305–1318 (2003).
   PubMed Web of Science ®Google Scholar
• Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut47(4), 589–594 (2000).
   PubMed Web of Science ®Google Scholar
• Parry S, Hanisch FG, Leir SH et al.N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology16(7), 623–634 (2006).
   PubMedGoogle Scholar
• Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: A family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci.41(2), 189–231 (2004).
   PubMed Web of Science ®Google Scholar
• Croce MV, Isla-Larrain M, Tur R, Rabassa ME, Segal-Eiras A. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients. Clin. Exp. Metastasis21(2), 139–147 (2004).
   PubMedGoogle Scholar
• Burke PA, Gregg JP, Bakhtiar B et al. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int. J. Oncol.29(1), 49–55 (2006).
   PubMedGoogle Scholar
• Demichelis SO, Alberdi CG, Servi WJ, Isla-Larrain MT, Segal-Eiras A, Croce MV. Comparative immunohistochemical study of MUC1 and carbohydrate antigens in breast benign disease and normal mammary gland. Appl. Immunohistochem. Mol. Morphol.18(1), 41–50 (2010).
   PubMedGoogle Scholar
• Wang PH, Li YF, Juang CM et al. Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. Gynecol. Oncol.83(1), 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Wang PH, Lo WL, Hsu CC et al. Different enzyme activities of sialyltransferases in gynecological cancer cell lines. Eur. J. Gynaecol. Oncol.23(3), 221–226 (2002).
   PubMedGoogle Scholar
• Zhu YT, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim. Biophys. Acta.1536(2–3), 148–160 (2001).
   PubMedGoogle Scholar
• Sewell R, Backstrom M, Dalziel M et al. The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated Sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem.281(6), 3586–3594 (2006).
   PubMed Web of Science ®Google Scholar
• Picco G, Julien S, Brockhausen I et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology20(10), 1241–1250 (2010).
   PubMed Web of Science ®Google Scholar
• Jun L, Yuanshu W, Yanying X et al. Altered mRNA expressions of sialyltransferases in human gastric cancer tissues. Med. Oncol. DOI: 10.1007/s12032-010-9771-1 (2010) (Epub ahead of print).
   Google Scholar
• Vazquez-Martin C, Cuevas E, Gil-Martin E, Fernandez-Briera A. Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology67(2), 159–165 (2004).
   PubMedGoogle Scholar
• Bouanene H, Sahrawi W, Mokni M et al. Correlation between heterogeneous expression of sialyltransferases and MUC16 in ovarian tumor tissues. Onkologie34(4), 165–169 (2011).
   PubMedGoogle Scholar
• Gendler SJ. MUC1, the renaissance molecule. J. Mammary Gland. Biol.6(3), 339–353 (2001).
   PubMed Web of Science ®Google Scholar
• Lee G, Ge BX, Huang TK, Zheng G, Duan JT, Wang IHY. Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomark.6(2), 111–117 (2010).
   PubMedGoogle Scholar
• Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am. J. Clin. Pathol.122(1), 61–69 (2004).
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Al Masri A, Adriance MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene23(34), 5739–5747 (2004).
   PubMed Web of Science ®Google Scholar
• Kesisis G, Kontovinis LF, Gennatas K, Kortsaris AH. Biological markers in breast cancer prognosis and treatment. J. Buon.15(3), 447–454 (2010).
   PubMedGoogle Scholar
• Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst.88(20), 1456–1466 (1996).
   PubMed Web of Science ®Google Scholar
• Walsh MD, Luckie SM, Cummings MC, Antalis TM, McGuckin MA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res. Treat.58(3), 255–266 (1999).
   PubMed Web of Science ®Google Scholar
• Al-Azawi D, Kelly G, Myers E et al. CA 15–13 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer6, 220 (2006).
   PubMed Web of Science ®Google Scholar
• Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res. Treat.76(2), 95–102 (2002).
   PubMedGoogle Scholar
• Workman HC, Miller JK, Ingalla EQ et al. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Research11(5), R70 (2009).
   Google Scholar
• Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim. Biophys. Acta.1815(2), 224–240 (2011).
   PubMed Web of Science ®Google Scholar
• Moritani S, Ichihara S, Hasegawa M et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum. Pathol.39(5), 666–671 (2008).
   PubMedGoogle Scholar
• Cozzi PJ, Wang J, Delprado W et al. Muc1, Muc2, Muc4, Muc5ac and Muc6 expression in the progression of prostate cancer. Clin. Exp. Metastas.22(7), 565–573 (2005).
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol. Urol.3(3), 163–167 (1999).
   PubMedGoogle Scholar
• Pemberton L, Taylor-Papadimitriou J, Gendler SJ. Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals. Biochem. Biophys. Res. Commun.185(1), 167–175 (1992).
   PubMed Web of Science ®Google Scholar
• Price MR, Rye PD, Petrakou E et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17–23, 1996. Tumour Biol.19(Suppl. 1), 1–20 (1998).
   PubMed Web of Science ®Google Scholar
• O’Connor JC, Julian J, Lim SD, Carson DD. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis.8(1), 36–44 (2005).
   PubMedGoogle Scholar
• Capstick V, Maclean GD, Suresh MR et al. Clinical evaluation of a new two-site assay for CA125 antigen. Int. J. Biol. Markers6(2), 129–135 (1991).
   PubMedGoogle Scholar
• Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. Ca 125: the past and the future. Int. J. Biol. Marker13(4), 179–187 (1998).
   PubMed Web of Science ®Google Scholar
• Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene29(20), 2893–2904 (2010).
   PubMed Web of Science ®Google Scholar
• Van Elssen CH, Frings PW, Bot FJ et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology57(4), 597–606 (2010).
   PubMedGoogle Scholar
• Budiu RA, Mantia-Smaldone G, Elishaev E et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol. Immunother.60(7), 975–984 (2011).
   PubMed Web of Science ®Google Scholar
• Seregni E, Botti C, Lombardo C et al. Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res.16(4B), 2209–2213 (1996).
   PubMed Web of Science ®Google Scholar
• Lopez-Ferrer A, Curull V, Barranco C et al. Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am. J. Respir. Cell. Mol. Biol.24(1), 22–29 (2001).
   PubMed Web of Science ®Google Scholar
• Guddo F, Giatromanolaki A, Koukourakis MI et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J. Clin. Pathol.51(9), 667–671 (1998).
   PubMed Web of Science ®Google Scholar
• Ohgami A, Tsuda T, Osaki T et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann. Thorac. Surg.67(3), 810–814 (1999).
   PubMed Web of Science ®Google Scholar
• MacDermed DM, Khodarev NN, Pitroda SP et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med. Genomics3, 16 (2010).
   PubMed Web of Science ®Google Scholar
• Kuemmel A, Single K, Bittinger F et al. TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer63(1), 98–105 (2009).
   PubMedGoogle Scholar
• Kwon KY, Ro JY, Singhal N et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch. Pathol. Lab. Med.131(4), 593–598 (2007).
   PubMed Web of Science ®Google Scholar
• Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun.3, 3 (2003).
   PubMedGoogle Scholar
• Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther.6(4), 481–486 (2007).
   PubMed Web of Science ®Google Scholar
• Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy2(3), 305–327 (2010).
   PubMed Web of Science ®Google Scholar
• Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol.24(4), 571–578 (2006).
   PubMed Web of Science ®Google Scholar
• Buckman R, De Angelis C, Shaw P et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol. Oncol.47(1), 102–109 (1992).
   PubMed Web of Science ®Google Scholar
• Oei AL, Massuger LF, Oyen WJ. Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother. Radiopharm.22(4), 508–514 (2007).
   PubMedGoogle Scholar
• Ocean AJ, Guarino MJ, Pennington KL et al. Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). J. Clin. Oncol.29(4 Suppl.), 240 (2011).
   Google Scholar
• Gulec SA, Cohen SJ, Pennignton KL et al. Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a Phase I single-dose escalation trial. Clin. Cancer Res.17(12), 4091–4100 (2011).
   PubMed Web of Science ®Google Scholar
• Gold DV, Goggins M, Modrak DE et al. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev.19(11), 2786–2794 (2010).
   PubMedGoogle Scholar
• Chen Y, Clark S, Wong T et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res.67(10), 4924–4932 (2007).
   PubMed Web of Science ®Google Scholar
• Rubinstein DB, Karmely M, Pichinuk E et al. The MUC1 oncoprotein as a functional target: immunotoxin binding to α/β junction mediates cell killing. Int. J. Cancer124(1), 46–54 (2009).
   PubMedGoogle Scholar
• Dharma Rao T, Park KJ, Smith-Jones P et al. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl. Immunohistochem. Mol. Morphol.18(5), 462–472 (2010).
   PubMedGoogle Scholar
• Bitler BG, Menzl I, Huerta CL et al. Intracellular MUC1 peptides inhibit cancer progression. Clin. Cancer Res.15(1), 100–109 (2009).
   PubMed Web of Science ®Google Scholar
• Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol. Ther.8(13), 1197–1203 (2009).
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Joshi MD et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res.69(12), 5133–5141 (2009).
   PubMed Web of Science ®Google Scholar
• Joshi MD, Ahmad R, Yin L et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol. Cancer Ther.8(11), 3056–3065 (2009).
   PubMedGoogle Scholar
• Zhou Y, Rajabi H, Kufe D. Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol. Pharmacol.79(5), 886–893 (2011).
   PubMed Web of Science ®Google Scholar
• Torres MP, Ponnusamy MP, Chakraborty S et al. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther.9(5), 1419–1431 (2010).
   PubMed Web of Science ®Google Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res.13(15 Pt 2), s4652–s4654 (2007).
   PubMed Web of Science ®Google Scholar
• Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin. Biol. Ther.7(11), 1723–1730 (2007).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol.3(7), 735–744 (2008).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med.5, 60 (2007).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res.14(10), 3060–3069 (2008).
   PubMed Web of Science ®Google Scholar
• Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev. Vaccines7(7), 963–975 (2008).
   PubMed Web of Science ®Google Scholar
• Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control Release153(1), 16–22 (2011).
   PubMed Web of Science ®Google Scholar
• Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol.27(6), 289–301 (2006).
   PubMed Web of Science ®Google Scholar
• Glazer ES, Zhu C, Massey KL et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin. Cancer Res.16(23), 5712–5721 (2010).
   PubMed Web of Science ®Google Scholar
• Constantinou PE, Danysh BP, Lukianova-Helb EY, Lapotko DO, Carson DD. Targeted nanoparticle delivery and cytolysis. Presented at: Nano in Cancer: Linking Chemistry, Biology, and Clinical Applications In Vivo (AACR Special Conference). Miami, FL, USA, 12–15 January 2011.
   Google Scholar